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Wnt signallingPTPN13 is a high-molecular weight intracellular phosphatase with several isoforms that exhibits a highly
modular structure. Although in recent years different roles have been described for PTPN13, we are still far
from understanding its function in cell biology. Here we show that PTPN13 expression is activated during
megakaryocytic differentiation at the protein and mRNA level. Our results show that the upregulation of
PTPN13 inhibits megakaryocytic differentiation, while PTPN13 silencing triggers differentiation. The ability of
PTPN13 to alter megakaryocytic differentiation can be explained by its capacity to regulate ERK and STAT
signalling. Interestingly, the silencing of β-catenin produced the same effect as PTPN13 downregulation. We
demonstrate that both proteins coimmunoprecipitate and colocalise. Moreover, we provide evidence showing
that PTPN13 can regulate β-catenin phosphorylation, stability and transcriptional activity. Therefore, the ability
of PTPN13 to control megakaryocytic differentiation must be intimately linked to the regulation of β-catenin
function. Moreover, our results show for the ﬁrst time that PTPN13 is stabilised upon Wnt signalling, which
makes PTPN13 an important player in canonical Wnt signalling. Our results show that PTPN13 behaves as
an important regulator of megakaryocytic differentiation in cell lines and also in murine haematopoietic
progenitors. This importance can be explained by the ability of PTPN13 to regulate cellular signalling, and
especially through the regulation of β-catenin stability and function. Our results hold true for different
megakaryocytic cell lines and also for haematopoietic progenitors, suggesting that these two proteins may play
a relevant role during in vivo megakaryopoiesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
PTPN13 (a.k.a. PTP-Bas, PTPL1, hPTP1E, FAP-1, and PTP-BL in mice,
hereafter referred to as mPTPN13) is a high-molecular weight intracel-
lular phosphatase with several isoforms that shows a highly modular
structure. Besides the catalytic PTP domain at the C-terminus, it has a
KINDdomain, a FERMdomain and 5 PDZ domains. This structure allows
PTPN13 to maintain numerous interactions with a variety of ligands
(reviewed in [1]), which, besides its catalytic ability, suggests an impor-
tant role as a scaffolding protein. PTPN13 is broadly distributed in
different tissues [1] and its expression is regulated throughout mouse
development. Its mRNA is ubiquitously expressed in early embryos,a y BiologíaMolecular, Lab. 122,
07 Salamanca, Spain. Tel.: +34
ndez).but at later stages its distribution seems to be restricted to epithelial
or neuronal tissues [2], suggesting an important developmental role.
In zebraﬁsh, the knockdown of PTPN13 causes severe defects in cell
migration during gastrulation [3]. Deletion of the mPTPN13 catalytic
domain hampers motor nerve repair in mice [4], while mPTPN13-
deﬁcient mice show an enhanced differentiation of T helper cells [5].
Although it has been suggested that PTPN13 would be involved in
apoptosis, cytokinesis and cell cycle progression (reviewed in [1,6]),
its role in cell biology remains a puzzle. Moreover, several studies
have demonstrated the involvement of PTPN13 in cancer. Its expression
is altered in different types of cancer, and it seems that, depending on
the context, this protein could play a role as a tumour suppressor or
tumour promoter (reviewed in [7]).
The canonical Wnt pathway involves the stabilization of β-catenin,
an intriguing protein because of its dual independent functions as a
cell adhesion molecule and as a transcription cofactor [8]. The phos-
phorylation of β-catenin at serine and threonine residues by GSK3 and
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catenin can also be phosphorylated at tyrosine residues; this has been
linked to the regulation of its interaction with cadherin [10], its nuclear
localization [11] and its transcriptional activity [12]. This would imply
that β-catenin function could be regulated through dephosphorylation
by protein tyrosine phosphatases (PTPs). In fact, it has been suggested
that β-catenin could be regulated by different PTPs [10], including
PTPN13 [13,14].
In the present work we show that PTPN13 and β-catenin are impor-
tant regulators ofmegakaryocytic differentiation in bothmegakaryocyt-
ic cell lines and primary mouse haematopoietic progenitor cells. The
expression of PTPN13 is activated during megakaryocytic differentia-
tion and its upregulation or downregulation alters this process; this
can be explained in terms of the ability of PTPN13 to affect the signalling
pathways that are important for differentiation. Moreover, we have
observed that PTPN13 coimmunoprecipitates and colocalise with β-
catenin in megakaryocytic cells, and that its expression is activated
upon Wnt3a stimulation. Interestingly, the downregulation of β-catenin
produced a phenotype that was very similar to that produced by the
downregulation of PTPN13. We show that in this scenario β-catenin
stability and function are regulated by PTPN13, suggesting that the
importance of PTPN13 for megakaryocytic differentiation is intimately
linked to the regulation of β-catenin.
2. Materials and methods
2.1. Reagents
Cell culture media and supplements were from LONZA (Barcelona,
Spain). Thrombopoietin (TPO) and IL 1β were from Cellgenix GmbH
(Freiburg, Germany). Phorbol 12-myristate 13-acetate (PMA), dimethyl
sulfoxide (DMSO), TRI reagent, anti-β tubulin and MTT were from
Sigma-Aldrich Spain. Antibodies against PTPN13, p-ERK, ERK 1, Stat3,
Stat5, GATA-1, β-Catenin, β-Catenin and p-β-Catenin (S33, Y86 or
Y654) were from Santa Cruz Biotechnology, CA, USA. Antibodies against
p-Stat3 (Y705) and p-Stat5 (Y694)were fromCell signalling Technology,
Danvers MA, USA. Human CD41 and CD61 antibodies and the apoptosis
detection kit were from Inmunostep, Salamanca, Spain. Antibodies to
detect murines CD41 and CD61 were from eBioscience, Barcelona,
Spain. Donkey anti-rabbit Alexa 488 and goat anti-mouse Alexa 568 and
Prolong Gold Antifade Reagent were from life Technologies, Madrid,
Spain. Polyethylenimine, Linear (MW 25,000) was from Polysciences,
Inc. (Eppelheim, Germany). G418 sulphate was from Calbiochem,
Darmstadt, Germany. RNAspin mini kit was from GE Healthcare Life
Sciences Europe (Barcelona, Spain). RevertAid M-MuLV retrotransciptase
and ribonuclease inhibitor were from Fermentas (Barcelona, Spain).
2.2. Cell lines
The human erythroleukemic HEL cells were grown in RPMI medium
supplemented with 10% FBS, 100 U/ml penicillin, 100 U/ml streptomy-
cin and 2 mM L-glutamine. The murine cell line L8057 was grown in
50% RPMI/50% IMDM, 15% FBS, 100 U/ml penicillin, 100 U/ml strepto-
mycin and 2 mM L-glutamine. Megakaryocytic differentiation was
induced by 20 nM PMA (K562 and HEL cells) or 100 nM PMA (L8057
cells) treatment. pHM6-PTPL1 and pHM6-PTPL1-C/S plasmids [15]
were used to generate stable cell lines over-expressing wild-type
PTPN13 or a catalytically inactive mutant. Cells were transfected by
electroporation and selected with G418 as reported previously [16].
2.3. Lentiviral production for RNA interference
Two different sequences were designed to generate small hairpin
RNAs (shRNA) in order to interferewith gene expression. The sequences
of shRNA1 and shRNA2 for each target were as follows: PTPN13: 5′-
CCATGAAGATTCTGATAAA-3′ and 5′-TGGACGAGTTCTAGAATTA-3′; β-Cat: 5′-CCATGGAACCAGACAGAAA-3′ and 5′-CCACTAATGTCCAGCGTTT-
3′; mPTPN13: 5′-GACCGAATTCGAGAGAGAT-3′ and 5′-CAAAGACGAT
TCCACTTAC-3′; mβ-Cat: 5′-AGGACAAGCCACAGGATTA-3′ and 5′-GCAC
CATGCAGAATACAAA-3′. An oligonucleotide against ﬁreﬂy luciferase
was used as a control [17]. Homology to unrelated genes was discarded
by Basic local alignment search tool analysis. Target sequences were
cloned into pLVTHM, as described previously [16]. For lentivirus produc-
tion, the packaging vectors pMD2G and psPAX2 together with pLVTHM
were transfected into 293T with 0.05 mg/ml polyethylenimine in
150 mM NaCl. Viral supernatants were harvested at 48 h and 72 h
after transfection and concentrated by ultracentrifugation at 76,000 ×g
for 2 h at 16 °C. Precipitated viruseswere resuspended in a small volume
and the viral titre was measured by the infection of 293T cells.
2.4. Cell line transduction with lentiviruses
HEL and L8057 cell lines were transduced with lentiviruses in low-
serum medium (1% FBS) by spinoculation (centrifugation at 1800 ×g,
90 min at 32 °C), and viruses were removed 24 h later. The efﬁciency
of transduction was monitored by GFP expression. A multiplicity of
infection (MOI) between 50 and 100 was used in order to achieve
complete infection of all target cells.
2.5. Megakaryocytic differentiation analyses
Megakaryocytic differentiationwas studied via analysis ofmegakaryo-
cytic markers (CD41 and CD61) by ﬂow cytometry and May–Grünwald–
Giemsa staining, as described elsewhere [16]. Acetylcholinesterase activ-
itywas used as amarker ofmegakaryocytic differentiation inmurine cells.
Activity was measured in permeabilized L8057 cells with 0.2% Triton X-
100, as described previously [18]. HEL cells treated with 20 nM PMA
during 7 days were ﬁxed with 2.5% paraformaldehyde (15 min, 4 °C),
permeabilized with 70% ethanol (30 min, 4 °C), and stained with
propidium iodide (PI) (50 μg/ml) in the presence of RNAse (50 μg/ml)
(1 h, 37 °C). Cells were acquired with a Becton-Dickinson, FACSCalibur
cytometer using CellQuest software (BD Biosciences), to assess DNA
content.
2.6. Immunoblotting and immunoprecipitation
Cells resuspended in MLB lysis buffer (25 mM HEPES, pH 7.5,
150 mM NaCl, 1% Igepal, 10% glycerol, 10 mM MgCl2, 1 mM EDTA,
25 mM NaF, 1 mM Na2VO4, plus proteinase inhibitors) were incubated
on ice for 20 min, and non-soluble material was eliminated by centrifu-
gation. Protein concentrations were determined using the Bradford
assay. The samples were then subjected to sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and the proteins were
transferred onto polyvinylidene ﬂuoride (PVDF) membranes, as
described previously [16]. Quantiﬁcation of bands was performed
by densitometry as previously described [19], and it is shown below
the blots. PTPN13 or β-catenin was immunoprecipitated with speciﬁc
antibodies and the proteins present in the immunoprecipitate were
analysed by immunoblotting.
2.7. Quantitative RT-PCR
RNAwas extractedwith TRI reagent (SIGMA). 200U of RevertAidM-
MuLV retrotransciptase was used to generate cDNA. The RT reaction
was performed at 37 °C for 1 h in the presence of 20 U of ribonuclease
inhibitor. The reactions were run for 40 cycles at the appropriate
annealing temperature for each pair of oligos on a StepOne Real-Time
PCR System (Applied Biosystems). Analysis of the PCR data was
performed with the comparative CT method (ΔΔCT) [20], using
actin as endogenous control. The oligo sequences were as follows:
Human actin: Forward: 5′-CACCACACCTTCTACAATGA-3′, Reverse:
5′-ACATGATCTGGGTCATCTTC-3′; PTPN13: Forward: 5′-AGTAAGCC
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Cat: Forward: 5′-TTGGTTCACCAGTGGATTCT-3′, Reverse: 5′-AATTTG
AAGGCAGTCTGTCG-3′.
2.8. Cell viability and proliferation analyses
Cell viability was determined by staining with annexin V-PE/7-AAD,
and proliferation was analysed by the MTT assay as described [16].
2.9. Immunocytochemistry
PTPN13, β-catenin and CD61 expressions were analysed by immu-
nocytochemistry as described previously [21]. Cells were ﬁxed with
2.5% paraformaldehyde (30 min, RT), permeabilized with 0.1% Triton
X-100 (10 min, RT), and blocked with 1% BSA (10 min, RT). Then, cells
were incubated with primary antibodies, rabbit anti-PTPN13 (1:50),
mouse anti-β-catenin (1:50), or mouse anti-CD61 (1:50) (2 h, RT).
Donkey anti-rabbit Alexa 488 (1:4000) and goat anti-mouse Alexa
568 (1:4000) were used as secondary antibodies (1 h, RT). Cells were
mounted with Prolong Gold Antifade reagent (Invitrogen). Images
were taken with a Leica TCS SP5 Confocal Laser Scanning Microscope,
using LAS AF software (Leica Application Suite Advanced Fluorescence).
2.10. Transcriptional analyses
A segment of 918 bp corresponding to the PTPN13/JNK3 (MAPK10)
bidirectional promoter was ampliﬁed by PCR and cloned into the pGL3
luciferase reporter plasmid. The forward and reverse oligo sequences
were as follows: 5′ GGGGTCGTCGGCTGCATTTTCAAC 3′ and 5′ GGAG
CGAAAGCAGAGAGAGGAGGAA 3′. This plasmid was transfected by
electroporation in HEL cells. Promoter activity was analysed bymeasur-
ing the luciferase activity of transfected cells. pCMV-βGal was used as a
transfection control.
The luciferase TOP-FLASH reporter was used to analyse β-catenin
transcriptional activity [12]. A stable β-catenin mutant was generated
by site-directed mutagenesis of S33Y and cloned into the pWPI vector.
The reporter plasmid was cotransfected into 293T cells in the presence
or absence of pWPI-β-catenin S33Y. pHM6-PTPL1 and pHM6-PTPL1-C/
S plasmids [15] were used to over-express wild-type PTPN13 or the
catalytically inactive mutant respectively. To interfere with PTPN13
expression, PTPN13-shRNA2 cloned into pLVTHMwas used, as described
above. Luciferase activitywas normalisedwith respect toβ-galactosidase
transfection control as done elsewhere [22].
2.11. Bone marrow cell puriﬁcation and lentiviral transduction
All animal protocols were approved by the University of Salamanca
Animal Care and Use Committee and were approved by the Bioethics
Committee of the University of Salamanca. C57BL/6 mice were pur-
chased from the University of Salamanca Animal Facility Unit. Lineage
marker-depleted (Lin−) cells puriﬁed from complete bone marrow
from mice by magnetic sorting, using the mouse Lineage cell depletion
kit (Miltenyi Biotec), according to the manufacturer's instructions. Lin−
cell lentiviral transduction was conducted by spinoculation as reported
above, with MOIs between 200 and 300 per cell, in IMDM, 20% FBS,
100 U/ml penicillin, 100 U/ml streptomycin and 2 mM L-glutamine,
supplemented with 10 ng/ml mSCF, 10 ng/ml mIL3, 10 ng/ml mTPO
and 10 ng/ml mFlt3-L [23]. 24 h later, after removal of the viruses, cells
were subjected to treatment with 100 ng/ml TPO and 10 ng/ml IL1β
over 6 or 12 days to induce ex vivo megakaryocytic differentiation.
Lentiviral transduced cells were identiﬁed byGFP expression, anddiffer-
entiation analysis was performed in these cells, analysing the levels
of megakaryocytic markers (CD41, CD61 and CD42a), ploidy, and the
colony forming ability. Colony forming assays were performed as
described before [19], in the presence of 100 ng/ml TPO and 10 ng/ml
IL1β. The number of megakaryocytic colonies was counted on day 14.2.12. Statistical analyses
Data are expressed as means ± SD. Statistical analyses were
performed using Student's t-test or analysis of variance (ANOVA)
followed by Scheffé test. Differenceswere considered statistically signif-
icant when p b 0.05.
3. Results
3.1. The upregulation of PTPN13 hinders megakaryocytic differentiation
PTPN13 is highly expressed in human platelets (our unpublished
data), which suggests a role for this protein in platelet physiology or
during megakaryocytic differentiation. Human HEL cells are often used
as a model to study megakaryocytic differentiation after stimulation
with low doses of phorbol esters [16]. We found that PTPN13 protein
expression increased during megakaryocytic differentiation in HEL
cells (Fig. 1A). To determine whether these results were due to protein
stabilization or to regulation at transcription level, we analysed PTPN13
mRNA levels and the activity of the ptpn13 gene promoter. Our results
showed that themRNA levels increased rapidly duringHEL cell differen-
tiation (Supplementary Fig. 1A) and, in agreement with this, we also
detected an increase in promoter activity in HEL cells upon PMA stimu-
lation (Fig. 1B). Together, these data suggest that ptpn13 gene transcrip-
tion is activated during megakaryocytic differentiation.
To test the involvement of PTPN13 inmegakaryocytic differentiation
we generated stable cell lines that overexpressed the protein (Fig. 1C).
PTPN13 overexpression signiﬁcantly decreased the levels of the CD41
and CD61 megakaryocytic markers, while the expression of CD45
haematopoietic marker remained unchanged (Fig. 1D and E). Neither
cell viability (Supplementary Fig. 1B) nor the proliferative capacity
(Supplementary Fig. 1C) was modiﬁed by PTPN13 overexpression.
Morphological analysis revealed that, after PMA stimulation, cells with
PTPN13 upregulation showed smaller size (Fig. 1F), and reduced
expression of CD61 at the cell surface (Fig. 1G), reﬂecting a less differen-
tiated phenotype. The frequency of polyploid cells was also reduced by
PTPN13 overexpression (Fig. 1H). Moreover, these effects did not seem
to be completely dependent on the catalytic activity of the protein, since
the overexpression of a catalytically inactive mutant produced an
outcome similar to that of the wild-type protein.
3.2. Dowregulation of PTPN13 triggers megakaryocytic differentiation
Next, we reduced PTPN13 levels in HEL cells with two different
shRNA sequences (Fig. 2A and B). The levels of megakaryocytic markers
were signiﬁcantly higher when the PTPN13 level was downregulated,
while the expression of CD45 haematopoietic marker remained
unchanged (Fig. 2C). At morphological level, in comparison with
control cells the downregulation of PTPN13 levels generated larger
cells (Fig. 2D), and immunostaining revealed a clear increase in CD61
expression at the cell surface (Fig. 2E), in keeping with the ﬂow cytom-
etry analysis (Fig. 2C). The frequency of polyploid cells after PMA stim-
ulation was also increased by PTPN13 silencing (Fig. 2F). PTPN13
silencing also impaired cell viability (Supplementary Fig. 1D) and the
cellular proliferation rate (Supplementary Fig. 1E).
Thedownregulation ofmPTPN13 inmouse L8057 cells (Supplementa-
ry Fig. 2A) led to higher acetylcholinesterase (AchE) activity (Supplemen-
tary Fig. 2B) and to a signiﬁcant increase in the levels of megakaryocytic
markers (Supplementary Fig. 2C). In conclusion, PTPN13 or mPTPN13 si-
lencing leads cells to exhibit a more differentiated phenotype.
3.3. Changes in the level of PTPN13 alter cellular signalling
Megakaryocytic differentiation is highly dependent on sustained
ERK activation [16,24], and also on the activation of STAT transcription
factors [25]. It has been described that PTPN13 can affect ERK signalling
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in a haematopoietic context [5]. To better understand how PTPN13
might regulate megakaryocytic differentiation, we analysed the levelof activation of ERK, STAT3 and STAT5 in stable cell lines in which
PTPN13 had been overexpressed or downregulated. The experiments
showed that the activation levels of the three signalling proteins
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2891J.L. Sardina et al. / Biochimica et Biophysica Acta 1843 (2014) 2886–2899decreased when PTPN13 was overexpressed (Fig. 3A) and increased
when the phosphatase was downregulated (Fig. 3B). Moreover, the
ability of PTPN13 to affect cell signalling did not seem to depend on its
catalytic ability, since overexpression of the PTPN13 catalytic inactive
mutant produced an effect similar to that caused by the wild-type
protein (Fig. 3A). Under PMA stimulation, the activation of ERK and
STAT5was alwaysmoremarked in cells inwhichPTPN13wasdownreg-
ulated than in control cells (Fig. 3C).We also looked at the levels of GATA-1, the master transcription
factor for erythrocytic and megakaryocytic differentiation. GATA-1
levels were reduced in cells overexpressing PTPN13, especially when
the wild-type version of the protein was upregulated (Fig. 3D, left
panel). Moreover, GATA-1 levels were elevated in cells knocked-down
for PTPN13 (Fig. 3D, right panel). This effect seemed to be speciﬁc for
GATA-1, since the expression of STAT5 transcription factor was not
affected by the modiﬁcation of PTPN13 levels.
2892 J.L. Sardina et al. / Biochimica et Biophysica Acta 1843 (2014) 2886–28993.4. PTPN13 and β-catenin coimmunoprecipitate and colocalise
The physical interaction betweenmPTPN13 and the tumour suppres-
sor APC has been described previously [13], and mPTPN13 seems to be
able to dephosphorylate β-catenin in pancreatic cells, thus antagonizing
Wnt signalling [14]. Bearing in mind these previous results, we were
prompted to analyse the possible relationship between PTPN13 and β-
catenin during megakaryocytic differentiation. To accomplish this, we
studied whether both proteins formed part of the same protein complex
in coimmunoprecipitation assays. We immunoprecipitated PTPN13 and
β-catenin from HEL cell extracts independently, and regardless of the
antibody used for the immunoprecipitation the other proteinwas always
present in the precipitate (Fig. 4A), showing that these two proteins
formed part of the same complex in haematopoietic cells.
Immunocytochemistry analyses revealed that both proteins were
distributed between the cytoplasm and the nucleus. Moreover, the
images showed a strong colocalisation signal for both proteins (Fig. 4B).
3.5. The dowregulation ofβ-catenin triggersmegakaryocytic differentiation
To test the possible role of β-catenin in megakaryocytic differentia-
tion we generated two stable HEL cell lines in which its expression
was downregulated with two different shRNAs (Fig. 5A and B). The
levels of megakaryocytic markers were signiﬁcantly higher when β-
catenin expression was downregulated, while the expression of the
CD45 marker was not affected (Fig. 5C). The interference of β-catenin
produced large cells,with amorphology reminiscent of that ofmegakar-
yocytes (Fig. 5D), with a higher expression of CD61 at the cell surface as
shown by immunostaining (Fig. 5E), in keepingwith the ﬂow cytometry
analysis. Moreover, GATA-1 protein was upregulated upon β-catenin
silencing (Fig. 5F). The frequency of polyploid cells was also augmented
by β-catenin silencing (Fig. 5G). As was the case of PTPN13, β-catenin
silencing seemed to impair cell viability (Supplementary Fig. 3A), and
the proliferation rate tended to be lower, although without statistical
signiﬁcance (Supplementary Fig. 3B). The silencing of mβ-catenin also
led to a more differentiated phenotype in the mouse L8057 cell line
(Supplementary Fig. 4). Interestingly, these features are very reminis-
cent of the downregulation of PTPN13 or mPTPN13, suggesting thatB
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Since one of the main ways of regulating β-catenin function is
through its stability, we next analysed whether PTPN13 was regulating
β-catenin turnover. Our results revealed that β-catenin levels were
higher in PTPN13 over-expressing cells (Fig. 6A, left panel), especially
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PTPN13 catalytic activity would be necessary to regulate β-catenin sta-
bility. In contrast, when PTPN13 was downregulated, β-catenin levels
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Moreover, β-catenin decay under cycloheximide treatment was notice-
ably faster in the cells in which PTPN13 had been knocked down
(Fig. 6B), suggesting that PTPN13 protects β-catenin from degradation.
Since β-catenin degradation is triggered by phosphorylation, we exam-
ined the levels of β-catenin Ser33 phosphorylation in the presence of
proteasome inhibitors to avoid protein degradation. It turned out that
this modiﬁcation was diminished in cells over-expressing PTPN13,
especially in cells over-expressing the wild-type protein, and was
augmented by PTPN13 knockdown (Fig. 6C). These results are consis-
tent with the notion that PTPN13 canmodulate β-catenin phosphoryla-
tion and turnover. Although it cannot be expected that PTPN13 would
regulate β-catenin Ser33 phosphorylation directly, PTPN13 catalytic
activity did seem to be necessary for this purpose, since the effects
detected were stronger in cells over-expressing the wild-type version
of PTPN13 than in those expressing a catalytically inactive mutant
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Besides the regulation of its stability, the regulation of β-catenin
transcriptional activity is also important to control its function. There-
fore, we wondered whether PTPN13 regulates the transcriptional activ-
ity of β-catenin. Since our data had shown that PTPN13 regulated β-
catenin stability, we decided to use a β-catenin S33Y stable mutant to
facilitate the readout from these experiments. Overexpression of β-
catenin S33Y alone produced a signiﬁcant increase in TOP-FLASH
reporter activity, as expected. Moreover, the tuning of PTPN13 levelswas seen to affect β-catenin transcriptional activity. When PTPN13
was knocked down, TOP-FLASH reporter activity was further increased
(Fig. 6E, left panel), suggesting that PTPN13 would inhibit β-catenin
transcriptional activity. In agreement with this, the overexpression of
PTPN13 decreased reporter activity signiﬁcantly (Fig. 6E, right panel).
β-Catenin phosphorylation at tyrosine 654 seems to increase the
binding of the protein to the basal RNA pol II machinery [12], and also
seems to be important for increasing β-catenin nuclear localization
[11]. These previous reports are in agreement with our ﬁndings, since
the strong increase in transcriptional activity detected when PTPN13
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tyrosine 654 phosphorylation, as observed (Fig. 6D).
3.8. PTPN13 is involved in the canonical Wtn/β-catenin signalling pathway
The coincidence in phenotype when PTPN13 and β-catenin are
silenced and the fact that PTPN13 regulates different aspects of β-
catenin function strongly suggested that these two proteins belonged
to the samepathway, andwe surmised that PTPN13 should be upstream
from β-catenin.
To test this further, the expression of PTPN13was downregulated in
one of the β-catenin-silenced cell lines (Fig. 7A). The double-silenced
cell line also showed signiﬁcantly higher levels of megakaryocytic
markers (Fig. 7B) and a higher proportion of polyploid cells (Fig. 7C),
in comparison with control cells. However, these features in the
double-silenced cell line were not increased when compared with the
parental cell line where only β-catenin was silenced. In other words,
the double silencing did not produce a stronger phenotype.
Moreover, β-catenin expression was downregulated in cells overex-
pressing PTPN13 (Fig. 7D). Interestingly, the decrease inmegakaryocyt-
ic markers and ploidy induced by PTPN13 overexpression was partially
rescued by β-catenin downregulation, levels very similar to those of
control cells being reached (Fig. 7E and F).
These results support the notion that PTPN13 and β-catenin belong
to the same pathway, PTPN13 being an upstream regulator of β-
catenin. β-Catenin stabilisation is one of the main features of the so-
called canonical Wnt pathway. This pathway has recently been related
to megakaryopoiesis [28,29], and hence we thought it of interest to
analyse whether PTPN13 was involved in this signalling. Our results
showed that the inhibition of GSK3β by lithium chloride treatment
induced a mild increase not only in β-catenin as expected, but also in
PTPN13 (Fig. 7G). Moreover, stimulation with Wnt3a induced the
stabilisation of both, β-catenin and PTPN13 (Fig. 7H), suggesting that
PTPN13 stabilisation must be part of the canonical Wnt pathway in
megakaryocytic cells. To the best of our knowledge, we show here for
the ﬁrst time that PTPN13 stabilisation must be part of the canonical
Wnt signalling pathway.
3.9. Downregulation of mPTPN13 or mβ-catenin triggers megakaryocytic
differentiation of haematopoietic progenitor cells
In order to check whether our observations were meaningful in a
more physiological context we decided to analyse the involvement
of both proteins in the megakaryocytic differentiation of murine
haematopoietic progenitor cells.
Under ex vivo culture conditions in the presence of TPO and IL1β,
murine bonemarrow Lin− cells undergomegakaryocytic differentiation,
as reﬂected by the signiﬁcant increase in the levels of megakaryocytic
markers (CD41 and CD61) (Fig. 8A and B). After 12 days of treatment
these cells showed a dramatic morphological change corresponding to
megakaryocytic differentiation (Fig. 8C).
To test the involvement of mPTPN13 or mβ-catenin in themegakar-
yocytic differentiation of the progenitor cells, shRNAs against mβ-
catenin or mPTPN13 were introduced into bone marrow Lin− cells by
lentiviral infection, and an shRNA against ﬁreﬂy luciferase was used
as a control [16,23]. The results showed that the interference of
mPTPN13 and mβ-catenin produced a more differentiated pheno-
type in murine haematopoietic progenitor cells, because these cells
showed a signiﬁcant increase in the levels of megakaryocytic markers
(Fig. 8D and E), and in the frequency of high-ploidy cells in comparison
with control cells (Fig. 8F). Moreover, the number of megakaryocytic
colonieswas increased bymβ-catenin silencing and tended to be higher
when mPTPN13 was downregulated (Fig. 8G).
In sum, these results strongly suggest that PTPN13 and β-catenin
may be important regulators of megakaryopoiesis in vivo.4. Discussion
PTPN13 is high-molecular weight phosphatase with a modular
structure. In spite of the broad number of interactions reported for
PTPN13 [1], its molecular function remains obscure. Here we studied
the role of PTPN13 and β-catenin in megakaryocytic differentiation. To
the best of our knowledge, this is the ﬁrst description of the importance
of PTPN13 in the homeostasis of megakaryocytic differentiation.
Our results show that the expression of PTPN13 is activated during
megakaryocytic differentiation at the protein andmRNA levels, suggest-
ing an important role for this protein during this differentiation. In
agreement with this, we found that altering PTPN13 levels dramatically
affected the differentiation of both, cell lines and haematopoietic
progenitors.
Experiments aimed at the overexpression or downregulation of
PTPN13 suggested that this protein would behave as a negative regula-
tor of megakaryocytic differentiation, probably through the regulation
of signalling pathways required for this process. It has been shown
previously that PTPN13 downregulation leads to a hyperactivation of
ERK signalling in epithelial cancer [26] and breast cancer [27] cells.
Consistent with this, we detected an increase in ERK activation when
PTPN13 was downregulated and observed the opposite result when
the phosphatase was upregulated. Moreover, we observed that PTPN13
was also able to inﬂuence the activation of STAT3 and STAT5, in agree-
ment with previous reports [5]. A sustained activation of ERK [24] and
STAT protein activation [30] is involved in megakaryocytic differentia-
tion. Our results are consistent with the notion that PTPN13 would con-
trol cellular signalling duringmegakaryocytic differentiation.We suggest
that PTPN13 upregulationmight be important for attenuating the signal-
ling cascades driving such differentiation. Interestingly, PTPN13 catalytic
activity did not seem to be required to mediate this effect, since overex-
pression of a catalytically inactive mutant or the wild type protein pro-
duced the same effect regarding differentiation and cellular signalling,
favouring a role as a scaffolding protein in this context.
Although signalling regulation by PTPN13 would explain its impor-
tance for maintaining megakaryocytic differentiation, we wondered
whether there might be additional mechanisms. We observed that
PTPN13 interacted with β-catenin in megakaryocytic cells. Interesting-
ly, we noted a striking coincidence in the phenotype elicited by the
silencing of β-catenin and PTPN13. Our results show that PTPN13 regu-
lates β-catenin stability. Curiously, while this workwas in preparation it
was reported that PTPN13 inﬂuences BCR-ABL-expressing cell prolifer-
ation and survival through the regulation of β-catenin stability [31].
Moreover, our results show that β-catenin regulation by PTPN13 is
not dependent exclusively on BCR-ABL signalling, and this may be
important in a physiological context, such asmegakaryocytic differenti-
ation for example, and not only for maintaining CML leukemic cell
proliferation and survival.
PTPN13 can reduce S33β-catenin phosphorylation, which increases
its stability. Owing to its catalytic speciﬁcity, PTPN13would be expected
to regulate S33β-catenin phosphorylation indirectly. Notwithstanding,
it is important to note that PTPN13 catalytic activity seems to be
required for the control of β-catenin stability, since overexpression of
a PTPN13 catalytically inactive mutant had a much weaker effect than
overexpression of the wild-type version of the protein.
Different aspects of β-catenin function, such as its interaction with
cadherin or its transcriptional activity, can be regulated by tyrosine
phosphorylation [32]. Upon PTPN13 silencing, a strong increase in β-
catenin phosphorylation occurs at tyrosines 86 and 654, together with
a strong increase in β-catenin transcriptional activity, suggesting that
PTPN13 could also regulate β-catenin transcriptional activity, modulat-
ing phosphorylation at certain tyrosine residues such as Tyr 654 [11,12].
Our results show that PTPN13 stabilisation is part of the canonicalWnt
signalling pathway,whichmust be important to increaseβ-catenin levels.
It has recently been suggested that Wnt signalling in megakaryocytes is
required for platelet formation [28]. However, another report suggests
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Fig. 8. Silencing of mPTPN13 or mβ-catenin triggers megakaryocytic differentiation of haematopoietic progenitors. Ex vivo megakaryocytic differentiation of Lin− cells puriﬁed from
mouse bone marrow. Differentiation was stimulated by treatment with 100 ng/ml TPO and 10 ng/ml IL1β for 6 or 12 days, and followed by analysis of speciﬁc markers (CD41, CD61
and CD42d). A) Flow cytometry diagram showing the percentage of CD41+CD61+ cells, B) and marker levels along differentiation. C) Cell staining with May–Grünwald–Giemsa at
days 0 and 12. Lin− cells were modiﬁed by lentiviral infection with shRNAs against mPTPN13 or mβ-catenin. An shRNA against ﬁreﬂy luciferase was used as a control. Cells carrying
the different shRNAswere identiﬁed byGFP expression. The levels of megakaryocyticmarkers at day 6 (D) and day 12 (E)were signiﬁcantly higher in cells transducedwith shRNA against
mPTPN13 or mβ-catenin. F) The DNA content was analysed at day 12. The percentage of high-ploidy cells is shown. G) Megakaryocytic colony-forming assay.
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cytes [29]. In agreement with this latter report, our results show that
PTPN13 and β-catenin levels can inﬂuence the ex vivo megakaryocytic
differentiation of murine haematopoietic progenitors. To reconcile these
apparently discrepant results, we suggest that the levels ofWnt signalling
must be strictly regulated during megakaryopoiesis. The stabilisation of
PTPN13 and β-catenin by Wnt signalling in megakaryocyte progenitors
must be important to control the balance between proliferation and
differentiation at this stage, and an excessive accumulation of these two
proteins would slow differentiation down. Moreover, a progressive
stabilisation of PTPN13 and β-catenin during differentiation would be
consistent with the involvement of Wnt signalling during later stages of
megakaryocyte maturation and platelet release, as suggested elsewhere
[28]. In the future it would be interesting to analyse the role of PTPN13
and β-catenin in terminal megakaryocyte maturation.
Finally, we show the importance of PTPN13 for the regulation of
megakaryocytic differentiation. In part, this can be explained through
the regulation of ERK or STAT signalling. Moreover, we believe that
the regulation of β-catenin stability and function by PTPN13 is essential
for the homeostasis of megakaryopoiesis. Here we provide strong
evidence of the existence of a functional relationship between PTPN13
and β-catenin during megakaryocytic differentiation. Moreover, we
show that PTPN13 levels increase upon Wnt3a signalling; this might
be important for β-catenin stabilisation, and places PTPN13 as a compo-
nent of canonical Wnt signalling. Our results hold true for megakaryo-
cytic cell lines and also for murine haematopoietic progenitors cells,
and hence we suggest that PTPN13 and β-catenin might be important
regulators of in vivo megakaryopoiesis. In future studies we shall
analyse the role of these proteins in other haematopoietic lineages.
5. Conclusions
Our results show that PTPN13 behaves as an important regulator
of megakaryocytic differentiation in cell lines and also in murine
haematopoietic progenitors. This can be explained by the ability of
PTPN13 to regulate the signalling pathways that control this type of dif-
ferentiation. Our data also show that β-catenin can also alter megakar-
yocytic differentiation. We show that PTPN13 regulates β-catenin
stability and function, as a part of canonical Wnt signalling, and that
this is required for correct cell differentiation.List of abbreviations
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